Biorithm, a pioneering women’s health MedTech company, has raised $3.5 million in Series A funding, co-led by Adaptive Capital Partners and SEEDS Capital, part of Enterprise Singapore. This investment marks a significant milestone in Biorithm’s mission to enhance pregnancy care globally.
Focused on reducing childbirth-related mortality, Biorithm is innovating with Femom, a technology for remote monitoring of maternal and fetal health. Femom integrates patient monitoring, personalized guidance, and predictive analytics to help clinicians identify early complications.
Amrish Nair, Biorithm’s CEO, expressed deep commitment to improving maternal health and preventing complications, highlighting the socio-economic challenges and technology limitations in maternal care worldwide.
The funding will fuel Biorithm’s expansion in Southeast Asia and the USA, supporting further research and clinical trials in these regions. Investors acknowledge Biorithm’s role in transforming women’s healthcare, emphasizing the importance of connected medical care for early intervention in pregnancy complications. Biorithm’s approach is set to revolutionize maternal health care, making it more accessible and personalized.
This story first appeared on AsiaTechDesk